Meat, Alcohol, and Obesity Raise Stomach Cancer Risk

Article

In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara examines a recent report that warns of different factors associated with an increased risk of stomach cancer.

In this Medical News Minute, developed exclusively for Cancer Network, Dr. Bobby Lazzara examines a joint report from the American Institute for Cancer Research and the World Cancer Research Fund that warns of different factors associated with an increased risk of stomach cancer. Among other findings, the report, “Diet, Nutrition, Physical Activity and Stomach Cancer,” found that the risk of cancers of the lower stomach increased by 18% for every 1.8 ounces of processed meat eaten per day.

Related Videos
Caitlin Costello, MD, with the Oncology Brothers
Caitlin Costello, MD, with the Oncology Brothers
Caitlin Costello, MD, with the Oncology Brothers
Caitlin Costello, MD, with the Oncology Brothers
A panel of 4 experts on lung cancer
A panel of 4 experts on lung cancer
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
D. Ross Camidge, MD, PhD, spoke about how the approval of alectinib is the beginning of multiple other approvals for patients with ALK-positive NSCLC.
Related Content
CheckMate-8HW assessed the efficacy of first-line nivolumab plus ipilimumab in patients with MSI-H/dMMR metastatic colorectal cancer.

Nivolumab/Ipilimumab Receive Type II Validation by EMA in MSI-H/dMMR mCRC

May 6th 2024
Article

CheckMate-8HW assessed the efficacy of first-line nivolumab plus ipilimumab in patients with MSI-H/dMMR metastatic colorectal cancer.

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice

May 6th 2024
Podcast

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

The regulatory agency has set a Prescription Drug User Fee Act date of February 28, 2025, for subcutaneous nivolumab in multiple solid tumors.

FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications

May 6th 2024
Article

The regulatory agency has set a Prescription Drug User Fee Act date of February 28, 2025, for subcutaneous nivolumab in multiple solid tumors.

Timothy Chen, MD, highlights how technologies such as ZAP-X and proton therapy may improve outcomes for patients with cancer.

Applying Novel Radiotherapy Technology for Brain Tumors and Other Cancers

April 29th 2024
Podcast

Timothy Chen, MD, highlights how technologies such as ZAP-X and proton therapy may improve outcomes for patients with cancer.

Data from a phase 2 study may support apalutamide plus androgen deprivation in high-risk localized prostate cancer following radical prostatectomy.

BCRFS Seen With Apalutamide Combo in Entire High-Risk Prostate Cancer Group

May 5th 2024
Article

Data from a phase 2 study may support apalutamide plus androgen deprivation in high-risk localized prostate cancer following radical prostatectomy.

67 Disparities in Regional Anesthesia Block Acceptance for Mastectomy With Reconstruction Surgery in a Standardized Setting

67 Disparities in Regional Anesthesia Block Acceptance for Mastectomy With Reconstruction Surgery in a Standardized Setting

May 4th 2024
Article